Genentech, Inc. Stock

Stocks

End-of-day quote NYSE
- ^USD	-

17/02/15	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
30/11/-1	GENENTECH : profit rises, sales top estimates	RE

17/02/15	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
30/11/-1	GENENTECH : profit rises, sales top estimates	RE
30/11/-1	GENENTECH : 3rd-quarter profit rises	RE
30/11/-1	GENENTECH : rejects Roche bid but willing to talk	RE
30/11/-1	GENENTECH : rejects Roche bid	RE
30/11/-1	GENENTECH : Roche buys Genentech for $46.8 billion	RE
30/11/-1	GENENTECH : Roche increases Genentech offer to $45.7 billion	RE
30/11/-1	GENENTECH : gives long-term forecast to fend off Roche	RE
30/11/-1	GENENTECH : to make case for higher purchase price	RE
30/11/-1	GENENTECH : asks shareholders to hold off on Roche bid	RE
30/11/-1	GENENTECH : Roche goes hostile, cuts Genentech bid to $42 billion	RE
30/11/-1	GENENTECH : forecast disappoints	RE
30/11/-1	GENENTECH : profit up, forecast light	RE

20/04/11	Genentech, Inc. : Dalradian Appoints Chief Operating Officer	PU
20/04/11	Genentech, Inc. : Dalradian Appoints Chief Operating Officer	PU
30/11/-1	GENENTECH : Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash	PR
30/11/-1	Genentech : Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer	BU
30/11/-1	Genentech : CORRECTING and REPLACING Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox	BU

12/04/16	Roche: la FDA homologue Venetoclax pour traiter une sorte de leucémie
11/04/16	Roche erhält von FDA Zulassung für Venetoclax zur Behandlung von Leukämie-Art
30/11/-1	Genentech : accroît de 7% son résultat net trimestriel.
30/11/-1	Genentech : l'offre de Roche considérée comme insuffisante.
30/11/-1	Genentech : s'envole après l'offre de Roche.

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.88%	+6.38%	+76.40%	+126.75%	1,119B
JOHNSON & JOHNSON	+1.07%	+3.80%	+50.73%	+62.78%	651B
ABBVIE INC.	+1.20%	+6.21%	+25.81%	+78.74%	468B
ROCHE HOLDING AG	+1.02%	+5.77%	+43.63%	+48.43%	374B
NOVARTIS AG	+0.85%	+4.07%	+24.97%	+40.58%	302B
ASTRAZENECA PLC	+1.26%	+6.81%	+2.27%	+14.41%	259B
AMGEN INC.	+1.88%	+5.81%	+49.57%	+70.53%	238B
NOVO NORDISK A/S	+1.59%	+2.09%	-17.33%	-52.62%	208B
GILEAD SCIENCES, INC.	+1.87%	+5.61%	+27.32%	+91.38%	181B
Average	+1.29%	+4.97%	+31.49%	+53.44%	422.21B
Weighted average by Cap.	+1.14%	+5.09%	+44.26%	+72.65%